Adults with type 2 diabetes on insulin glargine, who were treated with  tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, had greater reductions in HbA1c and body weight compared with placebo, according to data from the drug’s SURPASS trial program.  The findings of the trial, published in JAMA, showed  participants assigned 5 mg, 10 mg or 15 mg tirzepatide alongside once-daily insulin glargine had a greater decrease in HbA1c and body weight compared with placebo. Additionally, more than 85% of participants in all three tirzepatide groups had an HbA1c of less than 7% at 40 weeks.